Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

Fig. 3

Anti-Spike IgG, anti-Spike IgA and NAb levels by study groups. a Anti-Spike IgG levels by study subgroups (median), b NAb activity by study subgroups (median), c Anti-Spike IgA levels by study subgroups (median) (IS: Immunosuppressive group, HC: Healthy controls, INF: Infection group, NAb: Neutralizing antibody)

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us